Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.

Study summary:

Protocol for Extended Follow-up of a Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasia Type 2 (MacTel)


Inclusion Criteria: - The participant must be offered sufficient opportunity to review the informed consent form, agree to the form's contents and sign the protocol's informed consent; - The participant must have bilateral MacTel; - Women of childbearing potential and all men must agree to use an effective form of birth control during the study; - Participant must be medically able to undergo ophthalmic surgery for ECT implant; - The participant's best-corrected visual acuity 64 letters or better (20/50 or better) in the study eye; Exclusion Criteria: - Participant is < 21 years of age; - Participant is medically unable to comply with study procedures or follow- up visits; - Participant has evidence of ocular disease other than MacTel that may confound the outcome of the study (e.g., diabetic retinopathy with manifest macular edema, uveitis, etc.); - Participant has a chronic requirement (e.g., ≥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease, that in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted); - Participant has evidence of subretinal neovascularization in either eye; - Participant has evidence of central serous chorio-retinopathy (CSR) in either eye; - Participant has evidence of pathologic myopia in either eye; - Participant has had a vitrectomy, penetrating keratoplasty, trabeculectomy or trabeculoplasty;



Primary Contact:

Study Chair
Weng Tao
Neurotech USA

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.